My source was an institutional investor with frequent comunication with Halozyme. But it's not a secret, if you call the company yourself they will tell you the same (that they are told recently not to comment on PEGPH20). The "quite period" is not an official term. It was used by the institutional investor and not Halozyme. Nevertheless, halozyme is not commenting on PEGPH20 as adviced by legal recently and this is a change from just a couple of weeks ago. They have a winner and they want to squeaky clean on how they proceed.
News 
Market Data 
Discover 
